

WALLSTREETRESEARCH.ORG

NEW YORK, NY LOS ANGELES, CA PALM BEACH, FL



Pressure BioSciences, Inc.

Ticker: PBIO (OTCQB)

Corporate Profile

Page Lof 2

as of July 16, 2017

Pressure BioSciences, Inc. (OTCQB: PBIO) (PBI) is a medical research products, device, and technology company. PBI, based in South Easton, Massachusetts, serves academic and government laboratories, as well as biotechnology, pharmaceutical, and other life sciences companies. PBI develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated \$6 billion life sciences sample preparation market. PBI has installed approximately 300 sample preparation systems in approximately 160 sites worldwide. The Company's products are based on the unique properties of both constant and alternating hydrostatic pressure cycling technology, or PCT). The Company's primary sales focus is in the biomarker discovery and forensics sciences areas. The Company has products that can be used in other areas as well, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.

PBI has developed and patented a cutting-edge technology platform that can more accurately enable sample preparation, a critical process performed by thousands of scientists each day, which includes a wide range of activities that precede many forms of scientific analysis. PBI's products harness the unique properties of thermodynamics for life science research laboratories. Sample preparation processes play a major role in biological research. With an estimated 500,000 scientists in over 80,000 research laboratories worldwide, PBI's products could offer solutions for many scientists who are seeking ways to enhance the preparation of their samples. The PBI technology platforms are based on constant (i.e., static) and alternating (i.e., PCT) hydrostatic pressure; if used properly, pressure can help control the actions of molecules in biological samples, which can then have significant positive effects on scientific research studies. The Company offers products such as Barocycler Instruments, the Shredder System, and Consumables (PULSE and Micro Tubes). PBI holds 15 patents covering multiple applications of PCT that offer significant advantages over competitive methods used to prepare samples for research evaluation. It also has filed for a number of additional patents worldwide.

One of the major recent accomplishments PBI has achieved, is growth in the marketing of its products. PBI has significantly expanded the Company's focus and capabilities in the marketing and sales process, which will enable it to grow significantly for the remainder of 2017 and beyond. The Company has contracted with EKG Sales Associates, a life sciences lead generation service that has spent over 20 years developing their contact database with over 50,000 scientists and individuals from the life sciences field. With a focus on laboratory equipment and associated consumables, the new phase of marketing with EKG could be a significant jump-start for the Company. In addition, PBI recently hired two domestic sales executives to spearhead its growth and marketing initiatives and is planning on expanding its sales team with three additional field sales directors. PBI continues its two-year co-marketing agreement launched in 2016 with its large strategic partner named SCIEX, a global leader in life sciences analytical technologies and a wholly-owned subsidiary of the Danaher Corporation (NYSE: DHR). PBI also has developed relationships with distributors to market its products in Europe, Asia and the Pacific Rim.

With the recent increase in sales team efforts, PBI has seen products and services revenue increase 16% to \$525,998 for Q1 2017 as compared to \$454,350 for Q1 2016. This increase was primarily attributable to an increase of 19% in the sale of instrument systems, from \$332,016 in Q1 2016 to \$396,095 in the same quarter of 2017. Sales of consumables also increased during these same periods, from \$44,234 in Q1 2016 to \$63,264 in Q1 2017, an increase of 43%. Grant revenue however has decreased from \$56,128 in Q1 2016 to \$25,359 in Q1 2017. Despite the decrease in grant revenue, total revenue increased to \$551,357 for the three months ended March 31, 2017 as compared to \$510,478 during the three months ended March 31, 2016, an increase of \$40,878 or 8%. This increase was attributable to increases in the sales of its products and services via the newly established sales team. Operating loss decreased to \$999,103 in Q1 2017 from \$1,045,945 for the same period in 2016, a reduction of \$46,842 or 4%. This decrease was primarily due to reduced R&D expenses combined with increased sales of product and services.

The information presented herein is not to be construed as an offer to sell, nor a solicitation of

Barocyler ™ 2320 EXT





Sector: Healthcare

Industry: Medical Devices &

Technology

Website: www.pressurebiosciences.com

Key Statistics

Price	07/14/2017	6.89
52 We	13.80	
52 We	4.50	
Avg. V	2,348	
Beta	1.98	
Marke	7.32	
Price/	3.63	
Inside	r Ownership (%)	10%
Shares	1.10	
Float	(M)	1.01
EPS(tt	-2.40	

Source: Google / Yahoo Finance

Recent 2017 Highlights

- June 28, 2017, The Company filed an S-1 Registration Statement to offer up to 2 million units of its common stock and warrants, when declared effective.
- June 2, 2017, PBI announced that its one-for-thirty-reverse stock split became effective on June 5, 2017. The stock split was intended to increase the per share trading price of common stock.
- May 15, 2017, PBI announced record total revenues of \$551,357 for the first quarter, an increase of 8% over the prior year. The product and service revenues increased by 16% over the prior year.
- March 23, 2017, PBI announced a significant expansion effort on marketing and sales capabilities. The Company has joined forces with EKG Sales Associates, a life sciences lead generation service, and also hired two full-time field sales directors.
- February 9, 2017, PBI announced CE
 Marking for their next-generation Barocycler 2320EXTREME. This allows access
 to 31 countries in Europe that require the
 CE Mark prior to product commercialization. The Company also has a European
 distributor based in Germany, to handle
 sales and marketing activities in the European Union.

Corporate Contact Information

Pressure BioSciences, Inc. Richard T. Schumacher, CEO 14 Norfolk Ave. South Easton MA, 02375 Phone: 508-230-1828 www.pressurebiosciences.com

an offer to purchase, any securities. This corporate profile

is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to he accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investments in securities mentioned here contain inherent and significant risks, and are suitable only for speculative oriented investors. Any investments should only be made after consulting an investment professional. The featured company will pay a fee of \$3500 in cash to Alan Stone & Company LLC for preparation and distribution of this profile, including other potential fees associated with various consulting and investor relation services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.



\mathbf{W} all \mathbf{S} treet \mathbf{R} esearch.org

NEW YORK, NY LOS ANGELES, CA PALM BEACH, FL



Pressure BioSciences, Inc.

Ticker: PBIO (OTCQB)

Corporate Profile

Page 2 of 2 as of July 16, 2017

Sector: Healthcare

Industry: Medical Devices &

Technology

Website: www.pressurebiosciences.com

Last year, released its "next generation" Barocycler instrument, the 2320EXTREME. This release followed years of extensive user feedback. The compact, bench top instrument offers many features and benefits not found in its predecessor, including data logging options, user-level security, computer-operated control with touch screen programming, and the ability to customize multiple pressure cycling parameters. These new features and benefits should greatly expand the universe of potential users worldwide. With these enhanced capabilities, the 2320EXT has found a great reception from scientists involved in the cancer research project Cancer Moonshot. Formerly led by Vice President Joe Biden, this project aims to make more therapies available to more patients, while also improving the ability to prevent cancer to aid in its early detection. Cancer Moonshot is \$1 Billion dollar initiative, which started with \$195 million in new cancer activities at the National Institutes of Health (NIH) in 2016. In February, 2017, PBI has announced that it secured CE Marking for the Barocycler 2320EXTREME, which now enables the sales of its Barocycler instrument throughout all 31 European countries. The pursuit of global sales are becoming a key growth strategy for the company.

PBI recently had some high level recognition via one of its Barocyler 2320EXT scientific users, Dr. Ruedi Aebersole. Dr. Aebersole is a Professor of Systems Biology at the Institute of Molecular Systems Biology, who recieved the prestegious Karger Medal from the Barnett Institute of Chemical and Biological Analysis. Dr. Aebersole used PBI's instrument during his studies for proteomic sample preparation in biomarker discovery and other transformative research applications. Dr. Aebersold is a world renowned scientist and a pioneer in the field of proteomics, based in Zurich, Switzerland.

On June 28, 2017, the Company filed an S-1 Registration Statement with the SEC, and is planning on offering an aggregate of 1,993,223 shares of its common stock, and warrants to purchase 996,612 shares of its common stock. The warrants expire five years from the date of issuance. A warrant to purchase one share of common stock will accompany every two shares of common stock purchased. The shares and warrants will trade separately. PBI's common stock is presently quoted on the OTCQB under the symbol "PBIO". The Company has applied to have their common stock and warrants listed on The NASDAQ Capital Market under the symbols "PBIO" and "PBIOW," respectively. PBI's stock recently underwent a one-for-thirty reverse split of its common stock effective as of Monday, June 5, 2017. The shares underlying the Company's outstanding convertible securities were also adjusted accordingly. The reverse stock split served to increase the per share trading price of PBI's common stock to satisfy the \$4.00 minimum bid price requirement for initial listing on the NASDAQ Capital Market, however no assurance can be given as to if their application will be approved. As a result of the reverse stock split, every thirty shares of the Company's

common stock issued and outstanding prior to the opening of trading on June 5, 2017 was consolidated into one issued and outstanding share, with no change in the nominal par value per share. Immediately subsequent to the reverse stock split, there were approximately 1,055,232 shares of the Company's common stock issued and outstanding.

The Company continues to meet or exceed its goals, and is currently planning a public secondary stock and warrant unit offering. The offering, when completed, will materially improve the Company's balance sheet and should give the Company sufficient cash to greatly increase its revenue. We believe PBIO shares are significantly undervalued given its core technologies, the size of its market, its strong management team, expanded sales team marketing efforts, and the outlook for an improved financial position.



Income Statement	YE 2015	YE 2016	QTR Ended 3/31	Balance Sheet	YE 2015	YE 2016	QTR Ended 3/31	Cash Flow Statement	YE 2015	YE 2016	QTR Ended 3/31
Revenue	1,797,691	1,976,487	551,357	Cash & cash equivalents	116,783	138,363	121,438	Operating Cash Flow	(3,819,746)	(3,805,851)	(1,165,410)
Gross Profit	800,937	960,737	223,362	Total Assets	1,804,388	1,625,753	1,838,065	Investing Cash Flow	(9,412)	(7,203)	(15,608)
Operating Loss	(3,565,182)	(3,735,653)	(999,103)	Total Liabilities	9,782,036	10,009,171	15,302,548	Financing Cash Flow	3,471,993	3,834,634	1,164,093
Net Loss	(7,415,298)	(2,706,984)	(5,594,515)	Total Shareholder's Equity	(7,977,648)	(8,383,418)	(13,464,483)	Cash at end of period	116,783	138,363	121,438







The information presented herein is not to be construed as an offer to sell, nor a solicitation of an offer to purchase, any securities. This corporate profile is not a research report, but a compilation of information available to the public, which has been furnished by the featured company or gathered from other sources, in each case without independent verification, and no representations are made as to he accuracy or validity thereof. The information may include certain forward-looking statements within the meaning of Section 21E of the SEC Act of 1934, which may be affected by unforeseen circumstances or certain risks. Any investment in securities contains inherent risks and should only be done after consulting an investment professional. The featured company will pay a fee of \$3500 in cash to Alan Stone & Company LLC for preparation and distribution of this updated profile, including other potential fees associated with various consulting and investor relation services. For complete disclaimer information, the readers are hereby referred to the Disclaimer Page at the www.WallStreetResearch.org website.